SARTF (Sartorius AG) 3-Month Share Buyback Ratio: 0.00% (As of Mar. 2026 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SARTF Sartorius AG SARTF
84 GF Score
Price $212.80
GF Value $273.86
Valuation Modestly Undervalued
! 10 Warning Signs
View Full Analysis

What is Sartorius AG 3-Month Share Buyback Ratio?

Sartorius AG SARTF 84 3-Month Share Buyback Ratio is 0.00 as of Mar. 2026. GuruFocus rates SARTF with a GF Score™ of 84/100 and a GF Value™ of $273.86 (Modestly Undervalued). The stock has 10 warning signs investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Sartorius AG's current 3-Month Share Buyback Ratio was 0.00%.


Sartorius AG  (OTCPK:SARTF) 3-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


Sartorius AG 3-Month Share Buyback Ratio Related Terms


SARTF vs ISRG, BDX, MDLN: 3-Month Share Buyback Ratio Comparison

For the Medical Instruments & Supplies subindustry, Sartorius AG's 3-Month Share Buyback Ratio, along with its competitors' market caps and 3-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sartorius AG 3-Month Share Buyback Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's 3-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Sartorius AG's 3-Month Share Buyback Ratio falls into.


SARTF
84GF Score
Sartorius AG SARTF
3-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sartorius AG 3-Month Share Buyback Ratio Calculation

Sartorius AG's 3-Month Share Buyback Ratio for the quarter that ended in Mar. 2026 is calculated as

3-Month Share Buyback Ratio=(Shares Outstanding (EOP) (Dec. 2025 ) - Shares Outstanding (EOP) (Mar. 2026 )) / Shares Outstanding (EOP) (Dec. 2025 )
=(69.052 - 69.052) / 69.052
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a 3-Month Share Buyback Ratio of 0.00 mean?
Sartorius AG (SARTF) has a 3-Month Share Buyback Ratio of 0.00 as of Mar. 2026. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Sartorius AG and its competitors.
Is Sartorius AG's 3-Month Share Buyback Ratio too high?
Sartorius AG's current 3-Month Share Buyback Ratio is 0.00. Overall, Sartorius AG has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius AG's 3-Month Share Buyback Ratio compare to ISRG and BDX?
Sartorius AG's 3-Month Share Buyback Ratio of 0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Medical Devices & Instruments company?
A good 3-Month Share Buyback Ratio depends on the Medical Devices & Instruments industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Sartorius AG and its competitors. Sartorius AG's current 3-Month Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius AG stock overvalued right now?
Based on GuruFocus' analysis, Sartorius AG (SARTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $273.86, compared to a current price of $212.80 — trading 22.3% below its estimated fair value. The current 3-Month Share Buyback Ratio is 0.00. Sartorius AG's overall GF Score™ is 84/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For Sartorius AG (SARTF), the current 3-Month Share Buyback Ratio is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sartorius AG (SARTF) Overvalued in 2026?

Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued. The current stock price of $212.80 is trading 22.3% below its estimated GF Value™ of $273.86. GuruFocus considers Sartorius AG to be Modestly Undervalued.

Key valuation signals for SARTF:

  • 3-Month Share Buyback Ratio: 0.00
  • GF Value™: $273.86 vs. price of $212.80 (22.3% below fair value)
  • GF Score™: 84/100 with 10 warning signs

No single metric tells the full story. See the SARTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sartorius AG Business Description

Address Otto-Brenner-Strasse 20, Gottingen, NI, DEU, 37079
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
84GF Score

Get the complete analysis for SARTF

3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$212.80
Price
$273.86
GF Value